Semaglutide

Semaglutide is a long-acting glucagon-like peptide-1 (GLP-1) receptor agonist developed by Novo Nordisk, marketed as Ozempic for type 2 diabetes and Wegovy for weight management. It activates GLP-1 receptors in the brain and pancreas, suppressing appetite, increasing satiety, slowing gastric emptying, and enhancing insulin secretion. In the landmark SELECT trial, semaglutide 2.4mg weekly reduced cardiovascular events by 20% in patients with overweight/obesity and existing cardiovascular disease, achieving mean weight loss of 15.2% over 104 weeks. Its clinical advantages include robust cardiovascular protection, a well-established safety profile, and demonstrated benefits for metabolic liver disease.

15mg